Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 197 of the 201 references it cites were found in a registry or an index.

Clinical Pharmacokinetics and Pharmacodynamics of Propofol

Open access
Sahinovic, Marko M., Struys, Michel M. R. F., Absalom, Anthony R. · 2018 · Clinical Pharmacokinetics

Abstract

receptor, and has gained widespread use due to its favourable drug effect profile. The main adverse effects are disturbances in cardiopulmonary physiology. Due to its narrow therapeutic margin, propofol should only be administered by practitioners trained and experienced in providing general anaesthesia. Many pharmacokinetic (PK) and pharmacodynamic (PD) models for propofol exist. Some are used to inform drug dosing guidelines, and some are also implemented in so-called target-controlled infusion devices, to calculate the infusion rates required for user-defined target plasma or effect-site concentrations. Most of the models were designed for use in a specific and well-defined patient category. However, models applicable in a more general population have recently been developed and published. The most recent example is the general purpose propofol model developed by Eleveld and colleagues. Retrospective predictive performance evaluations show that this model performs as well as, or even better than, PK models developed for specific populations, such as adults, children or the obese; however, prospective evaluation of the model is still required. Propofol undergoes extensive PK and PD interactions with both other hypnotic drugs and opioids. PD interactions are the most clinically significant, and, with other hypnotics, tend to be additive, whereas interactions with opioids tend to be highly synergistic. Response surface modelling provides a tool to gain understanding and explore these complex interactions. Visual displays illustrating the effect of these interactions in real time can aid clinicians in optimal drug dosing while minimizing adverse effects. In this review, we provide an overview of the PK and PD of propofol in order to refresh readers' knowledge of its clinical applications, while discussing the main avenues of research where significant recent advances have been made.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40262-018-0672-3

Cites

197 of 197 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Propofol metabolic pathway. CYP cytochrome P450, UDP uridine 5′-diphosphate
Fig. 1 Propofol metabolic pathway. CYP cytochrome P450, UDP uridine 5′-diphosphateCC BY-NC · PubMed Central
Fig. 2 Overview of a three-compartment pharmacokinetic/pharmacodynamic model
Fig. 2 Overview of a three-compartment pharmacokinetic/pharmacodynamic modelCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 201 references

Research works printed but not linked: 5

  1. Glen JB, James R. 2,6-Diisopropylphenol as an anaesthetic agent. London: United States Patent and Trademark Office; 1977. p. 1–10.
  2. Schüttler J, Schwilden H, editors. Modern anesthetics (handbook of experimental pharmacology), vol. 182. Heidelberg: Springer; 2008.
  3. Pubchem. Propofol. 2017. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/propofol#section=Top .
  4. Hardman JG, Hopkins PM, Struys MMR, editors. Oxford textbook of anaesthesia. Oxford: Oxford University Press; 2017.
  5. Ure RW, Dwyer SJ, Blogg CE, White AP. Patient-controlled anxiolysis with propofol. Br J Anaesth. 1991;67:857P–8P.

Cited by

See all 890

Metadata

Authors
Sahinovic, M. M., Struys, M. M. R. F., & Absalom, A. R.
Affiliations
University Medical Center Groningen (NL)
Corresponding author
Sahinovic, Marko M.
Venue
Clinical Pharmacokinetics
Published
2018-07-18
Volume
57
Issue
12
Pages
1539-1558
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2883595456
Cited by
809
References
201
Citations by year
2026: 132 · 2025: 148 · 2024: 140 · 2023: 136 · 2022: 103 · 2021: 66 · 2020: 60 · 2019: 19 · 2018: 2
FWCI
9.03
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/4.0 (tdm)
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by-nc)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
  • Health Sciences › Veterinary › Small Animals › Veterinary Pharmacology and Anesthesia
  • Health Sciences › Medicine › Physiology (medical) › Biomedical and Chemical Research
Keywords
propofol, pharmacokinetics, pharmacodynamics, general anesthesia, target-controlled infusion, pharmacokinetic modeling, pharmacodynamic modeling, drug interactions, hypnotics, opioid synergy, response surface modelling, adverse effects, drug dosing
MeSH terms
Adult, Animals, Child, Dose-Response Relationship, Drug, Drug Interactions, Humans, Hypnotics and Sedatives, Models, Biological, Obesity, Propofol, Anesthetics, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Pharmacokinetics and Pharmacodynamics of Propofol. https://app.cochat.ai/papers/10.1007/s40262-018-0672-3
The paper
Sahinovic, M. M., Struys, M. M. R. F., & Absalom, A. R. (2018). Clinical Pharmacokinetics and Pharmacodynamics of Propofol. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-018-0672-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.